Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
30 juli, 14:01
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
PR Newswire
NEW YORK, July 30, 2025
Conference Call and Webcast at 8:30 AM Eastern Time
NEW YORK , July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025 , at 8:30 AM ET . During the call, Lishan Aklog , M.D. , Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath , Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 financial results.
The webcast will be available at the investor relations section of the Company's website at luciddx.com . Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com .
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard ® Esophageal DNA Test , performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device , represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com .
SOURCE Lucid Diagnostics
Ämnen i artikeln
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
30 juli, 14:01
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
PR Newswire
NEW YORK, July 30, 2025
Conference Call and Webcast at 8:30 AM Eastern Time
NEW YORK , July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025 , at 8:30 AM ET . During the call, Lishan Aklog , M.D. , Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath , Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 financial results.
The webcast will be available at the investor relations section of the Company's website at luciddx.com . Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com .
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard ® Esophageal DNA Test , performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device , represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com .
SOURCE Lucid Diagnostics
Ämnen i artikeln
Handelskrig
Apple
Analys
Handelskrig
Mest läst
Apple
Analys
Senaste nytt
Kempower
Igår, 12:28
Laddat för tillväxt i Kempower
Marknadsöversikt
OMX Stockholm 30
1 DAG %
−1,80%
Senast
2 533,59
1 mån
Loading market data...
Privatekonomi med Placeras expert
Affärsvärlden
